Maternal Plasma miRNAs Expression in Preeclamptic Pregnancies

Abstract EN

Preeclampsia (PE) is a pregnancy-specific syndrome and one of the leading causes of maternal and fetal morbidity and mortality.

The pathophysiological mechanisms of PE remain poorly known.

Recently, circulating miRNAs are considered as potential useful noninvasive biomarkers.

The aim of this study was to identify differentially expressed plasma miRNAs in preeclamptic pregnancies compared with normal pregnancies.

Methods.

Maternal plasma miRNA expression profiles were detected by SOLiD sequencing.

Differential expressions between mPE/sPE and control group were found.

Next, four differentially expressed plasma miRNAs were chosen to validate their expression in other large scale samples by real-time PCR.

Results.

In terms of sequencing results, we identified that 51 miRNAs were differentially expressed.

Four differentially expressed plasma miRNAs (miR-141, miR-144, miR-221, and miR-29a) were selected to validate the sequencing results.

RT-PCR data confirmed the reliability of sequencing results.

The further statistical analysis showed that maternal plasma miR-141 and miR-29a are significantly overexpressed in mPE (P<0.05).

Maternal plasma miR-144 is significantly underexpressed in mPE and sPE (P<0.05).

Conclusions.

Results showed that there were differentially expressed maternal plasma miRNAs in patients with preeclampsia.

These plasma miRNAs might be used as notable biomarkers for diagnosis of preeclampsia.